HRMY (Harmony Biosciences Holdings Inc.) stock: $42.02, $2.45B market cap, $667.8M cash, $1.91B EV, $3.22B fully diluted market cap. Next expected readout: Apr-27. Lead program: Pitolisant tablet (Prader-Willi Syndrome), Phase 3. Data from Fully Diluted's biotech stocks database.
Enterprise value
$1,913.3M
Balance sheet
| Cash | $667.8M |
|---|
| Debt | $134.0M |
|---|
| Net cash | $533.8M |
|---|
| Enterprise value | $1,913.3M |
|---|
| Basic shares | 58.1M shares |
|---|
| Fully diluted shares | 76.7M shares |
|---|
| Fully diluted market cap | $3,221.4M |
|---|
| Cash per share | $11.49 |
|---|
Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Price history
Loading HRMY daily closes…
Loading price history…
Upcoming catalysts
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|
| Dec 13, 2026 - Jan 24, 2027 | Clemizole HCl | Phase 3 | Lennox Gastaut Syndrome | — |
| May 13 - Jun 24 | Pitolisant tablet | Phase 3 | Prader-Willi Syndrome | — |
| May 13 - Jun 24 | Clemizole HCl | Phase 3 | Dravet Syndrome | — |
| Nov 12 - Dec 24 | HBS-301 tablet | Phase 3 | Idiopathic Hypersomnia | — |
| Nov 12 - Dec 24 | HBS-301 | Phase 3 | EDS; Cataplexy; Fatigue | — |
| Sep 12 - Oct 24 | Pitolisant | Phase 3 | Prader-Willi Syndrome | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Pipeline assets
WAKIX
Approved · Active
Aliases pitolisant
Target H3
Partnerships Bioprojet (2017 license agreement; exclusive US commercialization rights; tiered royalties)
Indications- narcolepsy: excessive daytime sleepiness and cataplexy in adults (FDA approvals 2019 and 2020) (Stage not disclosed)
- narcolepsy: excessive daytime sleepiness and cataplexy in pediatric patients 6 years and older (2024 and 2026) (Stage not disclosed)
Status note Company's only commercialized product; all revenue derived from WAKIX sales. Not scheduled as a controlled substance by the DEA.
pitolisant (Prader-Willi syndrome)
Stage not disclosed · Active
Target H3
Partnerships Bioprojet (2017 license agreement; PWS included in licensed field)
Indications- Prader-Willi syndrome (Stage not disclosed)
Status note Late-stage clinical program exploring pitolisant in PWS (filing-stated); phase and trial details not stated in the current 10-Q.
Pitolisant GR
Stage not disclosed · Active Modality: gastro-resistant formulation of pitolisant
Target H3
Partnerships Bioprojet (2022 license and commercialization agreement; exclusive US and Latin America rights to next-generation pitolisant products)
Indications- Prader-Willi Syndrome (Phase 3)
- Narcolepsy (Phase 3)
Status note Next-generation gastro-resistant pitolisant formulation in development.
Pitolisant HD
Stage not disclosed · Active Modality: high-dose formulation of pitolisant
Target H3
Partnerships Bioprojet (2022 license and commercialization agreement; exclusive US and Latin America rights to next-generation pitolisant products)
Indications- Prader-Willi Syndrome (Phase 3)
- Narcolepsy (Phase 3)
Status note Next-generation high-dose pitolisant formulation in development.
BP-205
Stage not disclosed · Active
Target orexin-2 receptor agonist
Partnerships Bioprojet (sublicense, April 2024; exclusive US and Latin America development, manufacturing and commercialization rights; rights originally licensed from Teijin Pharma)
Indications- narcolepsy (Stage not disclosed)
- other central nervous system indications (Stage not disclosed)
Status note In clinical development; a clinical milestone triggering a $4,250 payment to Bioprojet was achieved in November 2025.
EPX-100
Stage not disclosed · Active
Aliases clemizole hydrochloride
Target 5HT-2
Partnerships Epygenix Therapeutics (acquired April 2024; exclusive license for clemizole hydrochloride use)
Indications- Dravet syndrome (Stage not disclosed)
- Lennox-Gastaut syndrome (Stage not disclosed)
Status note Company's rare-epilepsy program; phase and trial details not stated in the current 10-Q.
CBS105
Discovery · Active Modality: cell replacement therapy
Partnerships CiRC Biosciences (research collaboration, option and license agreement, June 2025)
Indications- treatment-resistant narcolepsy (Stage not disclosed)
Status note Discovery-stage candidate under the CiRC Agreement.
CBS104
Discovery · Active Modality: cell replacement therapy
Partnerships CiRC Biosciences (research collaboration, option and license agreement, June 2025)
Indications- refractory epilepsy (Stage not disclosed)
Status note Discovery-stage candidate under the CiRC Agreement.
Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.